Reimagine Care's CEO says one-off hospital approvals slow CAR-T access and urges buyers to ask vendors to prove outcomes such as avoided ED visits.
|Videos|November 17, 2021
Jacqueline Glascock of Cure SMA Discusses FDA-Approved SMA Treatments & Dissects Combination Therapy
Author(s)Briana Contreras, Peter Wehrwein
Managed Healthcare Executive® recently interviewed Jacqueline Glascock, Ph.D., the director of research programs at Cure SMA, an nonprofit organization in Elk Grove, Illinois, that funds research into spinal muscular atrophy (SMA) and advocates for families and patients. In this video, Glascock discusses SMA and her organization, the three current therapies for the disease, and a combination therapy approach to the disease.
Advertisement
Advertisement
Related to this article
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
The financial pain from your healthcare cost is real, you are uniquely placed to negotiate prices down, and hospitals, at 46% of spending, are where to look, says the CEO and president of the Health Care Cost Institute, which issued its annual cost and utilization report today.
Spending on prescription drugs grew by 40%, faster than spending on inpatient care, outpatient care and professional services, according to a new report from the Health Care Cost Institute.
Meta-analysis links assisted reproduction tech (ART) to higher risks of major heart defects in pregnancies, urging targeted screening and long-term heart health follow-up.
A new Health Care Cost Instittue report finds prices, not utilization, drove spending growth in employer coverage from 2019 to 2023, echoing the group's very first report — and the title of Uwe Reinhardt's famous article.
Reading C-peptide alongside glucose could better predict which autoantibody-positive people will develop type 1 diabetes and detect treatment effects sooner.
Electronic health record developers, health plans, manufacturers and discount programs could support early prescribing decisions by enabling providers and patients to view more pricing options at the point of prescribing, says Joseph Kleiman, president of Buzz Health.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Chronic hand eczema needs more than topical steroids | Fall Clinical Derm 2026
2
Melanoma care is shifting to risk-based screening and treatment before surgery | Fall Clinical Derm 2026
3
U.S. employer-covered healthcare costs: It’s still the prices
4
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
5